Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05589896 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
A Phase 1 study of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Ossium Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 9
- Study locations
NCT05589896 is a Phase 1 study of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Ossium Health. The registered enrollment target is 12 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT05589896, a Phase 1 study of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Ossium Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.
Conditions Studied
Interventions
- OTHER Ossium HPC Marrow, Bone Marrow Transplant
- OTHER Pre-transplant conditioning - Myeloablative (MAC)
- OTHER Pre-transplant conditioning - Reduced Intensity (RIC)
- OTHER Post-transplant treatment
Study Locations (9)
Texas
- St. David's South Austin Medical Center - Austin
- Methodist Hospital, Texas Transplant - San Antonio
California
- City of Hope - Duarte
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University - Winship Cancer Institute - Atlanta
Michigan
- Henry Ford Cancer Institute - Detroit
Oregon
- Oregon Health and Science University - Portland
Tennessee
- TriStar Bone Marrow Transplant - Nashville
Utah
- University of Utah - Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05589896
The ClinicalTrials.gov registry entry for NCT05589896 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (90% lower). The listed sponsor is Ossium Health, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Ossium HPC Marrow, Bone Marrow Transplant is the first listed.
NCT05589896 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05589896 about?
NCT05589896 is a clinical study titled "A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies". The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or re...
What is the current status of trial NCT05589896?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-08-16. Estimated completion is 2027-03-31.
What conditions does trial NCT05589896 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Hodgkin's Lymphoma, Acute Biphenotypic Leukemia.
What interventions are being tested in trial NCT05589896?
The interventions under investigation include: Ossium HPC Marrow, Bone Marrow Transplant (OTHER), Pre-transplant conditioning - Myeloablative (MAC) (OTHER), Pre-transplant conditioning - Reduced Intensity (RIC) (OTHER), Post-transplant treatment (OTHER).
Who is sponsoring clinical trial NCT05589896?
This trial is sponsored by Ossium Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05589896 being conducted?
This trial has 9 study locations across California, Florida, Georgia, Michigan, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.